ABOUT

The Principals of Spruce Capital Partners are well known investors and thought leaders in the Life Sciences industry. They bring a wealth of experience as investors, advisers, and domain experts in helping entrepreneurs build the next generation of successful companies addressing global challenges. The Managing Partners have worked together for more than a decade shepherding investments across multiple funds and sectors.  

 

TEAM

 

PORTFOLIO

mlslogo2.png
Our portfolio consists of direct investments made by MLS Capital Fund II, a Venture Capital Fund co-managed by Spruce Capital Partners, LLC.
Show More

NEWS

 

April 04, 2019

NEW YORK (GenomeWeb) – Gene editing technology company Inscripta said today that it that its existing investors have agreed to contribute an additional $20 million to its previously announced Series C funding round, bringing the total raised in the round to $105.5 million.

In February 2018, the company said it had raised $55.5 million from Venrock, Foresite, Mérieux Développement, Paladin Capital Group, MLS Capital, and NanoDimension. In December, the same investors contributed an additional $30 million to the round, bringing the total to $85.5 million. The same investors have now contributed the additional $20 million, Inscripta said.

March 26, 2019

I’ve written about them several times over the last six months, and I bring them up in polite conversation more than I should. In my defense, I have a legitimate reason: cows, with their burps and farts, are a good example of something that contributes to climate change but isn’t related to generating electricity...

December 19, 2018

Existing investors contribute an additional $30 million to accelerate tools that will revolutionize genomic research

Boulder, CO – December 19, 2018 – Inscripta™, a leading gene-editing technology company, today announced that MAD7, its proprietary CRISPR enzyme, has achieved wide adoption by academic, commercial, and government researchers in its first year of availability. MAD7 was recently recognized by the Scientist magazine as one of the “Top 10 Innovations of 2018."

1 / 1

Please reload

CONTACT

 

Spruce Capital Partners

100 Montgomery St, Suite 2190

San Francisco, CA 94104

 

 

Submit a Business Plan or Contact Us: